

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

NCT06322238

Status	RECRUITING
Phase	Phase 2
Sponsor	Mayo Clinic
Enrollment	66 participants

Key Eligibility Criteria

Inclusion (7)

- In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Subject must be e 18 years old
- Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care.
- Subject is able and willing to take part and willing to be followed up on for 48 weeks
- Subject is able to donate saliva
- ... and 2 more (see full listing online)

Exclusion (14)

- For the investigational arm only: Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel
- Pregnant or lactating (to be verbally confirmed with the patient)
- Life expectancy estimated to be less than three months as determined by patient receiving hospice care
- Duration of index drug total treatment length is planned to be less than seven consecutive days.
- Current inpatients
- ... and 9 more (see full listing online)

Locations (1 total)

Mayo Clinic, Rochester, Minnesota, United States